华熙生物(688363)：改革初见成效 2025净利润预增55%-84%

Performance Overview - The company forecasts a net profit of between 270 million and 320 million for 2025, representing a year-on-year increase of 55% to 84%, with Q4 2025 net profit expected to be between 20 million and 70 million, indicating a turnaround from losses [1] - The annual non-GAAP net profit is projected to be between 170 million and 220 million, reflecting a year-on-year growth of 56% to 102%, with Q4 2025 non-GAAP net profit expected to range from -20 million to 30 million, indicating a reduction in losses or a turnaround [1] Commentary and Recommendations - In 2025, the chairman and general manager will lead the team back to the front lines, making adjustments to organizational structure, strategic planning, and product structure [2] - The company has improved operational efficiency and optimized operating costs, with a significant reduction in sales expense ratio by over 30% year-on-year, and a 6.8 percentage points decrease in the sales expense ratio for the first three quarters [2] - The company continues to deepen research in sugar biology and cell biology, laying a solid foundation for long-term development [2] - For 2026, the company is expected to continue improving operations, with stable growth in raw material business and strengthened competitive barriers due to ongoing optimization of production and research integration [2] - The medical terminal business saw a positive growth rate in Q3 2025, with a year-on-year revenue increase of 14.5%, and this positive trend is expected to continue into 2026 with improved channel structure and increased direct sales ratio [2] - The skin science innovation transformation business is entering a deep reform phase, focusing on fee structure, organizational structure, and strategic adjustments [2] - Profit forecasts remain unchanged, with expected net profits of 310 million, 530 million, and 600 million for 2025-2027, representing year-on-year increases of 76.4%, 72%, and 13.3% respectively, with EPS of 0.64 yuan, 1.10 yuan, and 1.24 yuan, corresponding to PE ratios of 70x, 41x, and 36x, maintaining a "range operation" investment recommendation [2]